Format

Send to

Choose Destination
Nanomedicine. 2011 Dec;7(6):859-70. doi: 10.1016/j.nano.2011.03.009. Epub 2011 Apr 13.

Enhanced antiproliferative activity of Herceptin (HER2)-conjugated gemcitabine-loaded chitosan nanoparticle in pancreatic cancer therapy.

Author information

1
Laboratory of Nanomedicine, Institute of Life Sciences, Bhubaneswar, India.

Erratum in

  • Nanomedicine. 2013 May;9(4):580.

Abstract

Currently, effective drug delivery in pancreatic cancer treatment is a major challenge. Nanomedicine plays an essential role by delivering anticancer drugs in a targeted manner to the malignant tumor cells, leading to increased efficacy by reducing the toxicity of anticancer drugs to normal, sensitive sites. This study investigated the preparation and characterization of a targeted system represented by Herceptin-conjugated gemcitabine-loaded chitosan nanoparticles (HER2-Gem-CS-NPs) for pancreatic cancer therapy. The targeted NPs displayed superior antiproliferative activity along with an enhanced S-phase arrest, leading to apoptosis in comparison with unconjugated gemcitabine-loaded nanoparticles and free gemcitabine due to higher cellular binding with eventual uptake and prolonged intracellular retention. Thus, HER2-Gem-CS-NPs are able to provide an efficient and targeted delivery of gemcitabine for pancreatic cancer treatment.

FROM THE CLINICAL EDITOR:

This study investigated the preparation and characterization of a targeted drug delivery system consisting of Herceptin-conjugated gemcitabine-loaded chitosan nanoparticles for pancreatic cancer therapy.

PMID:
21550422
DOI:
10.1016/j.nano.2011.03.009
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center